Septerna, Inc. (NASDAQ:SEPN) Chief Financial Officer Gil M. Labrucherie sold 20,000 shares of the company's common stock on November 16, 2026, generating proceeds of $832,359. The transaction was executed pursuant to a Rule 10b5-1 sales plan that Labrucherie had adopted on July 22, 2026.
The shares changed hands at prices spanning $41.4754 to $43.0. Since the sale, Septerna's stock has retreated to $39.45, a decline of 5.8% over the past week. Despite that recent softness, the shares have posted a 71% return over the trailing year, though data indicates the stock exhibits high volatility in its price movements.
Of the total shares sold, 15,815 were held directly by Labrucherie, while 4,185 were held indirectly by The Labrucherie Trust dated 9/1/2009, for which Labrucherie serves as trustee. Following these transactions, Labrucherie directly holds 7,002 shares, and the trust indirectly holds 20,000 shares of Septerna common stock.
The reported holdings also include 7,002 shares acquired through the Septerna, Inc. 2024 Employee Stock Purchase Plan (ESPP). These acquisitions consisted of 3,501 shares on October 31, 2025, and another 3,501 shares on April 30, 2026. Labrucherie disclaims beneficial ownership of the trust's shares except to the extent of his pecuniary interest.
According to analysis, the stock is currently trading near its Fair Value, with the company maintaining a GOOD financial health score.
In other recent developments, Septerna has drawn positive attention from analyst firms regarding its potential treatments. Guggenheim has raised its price target for Septerna to $65, maintaining a Buy rating, due to progress in the company's pipeline. The firm increased the probability of success for the oral small molecule PTH replacement SEP-479 to 50% from 35%. Additionally, Guggenheim has included risk-adjusted sales estimates for SEP-204, a Graves' disease treatment, with a 10% probability of success.
Similarly, Wells Fargo has increased its price target for Septerna to $61 from $50, maintaining an Overweight rating. This adjustment follows a detailed analysis of SEP-479, with Wells Fargo noting a more optimistic outlook compared to broader market expectations. The firm highlighted the potential for a favorable Phase 1 readout in the first quarter of 2027, should SEP-479 prove successful.
These recent developments reflect growing confidence among analysts in Septerna's drug candidates.